Terumo Neuro Unveils New SOFIA™ Flow 88 Neurovascular Aspiration Catheter Data from EMEA Demonstrating Strong Performance

Collected from 70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed: Collected from70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed: "TheSOFIAFlow 88 Neurovascular Aspiration Catheter represents a meaningful advancement in mechanical thrombectomy therapy across EMEA," saidCarsten Schroeder, President and CEO of Terumo Neuro. "Its super bore design maximizes aspiration and minimizes flow disruption while...

Collected from 70 procedures across 16 EMEA Hospitals and 31 physicians, the preference test revealed:

"The SOFIA Flow 88 Neurovascular Aspiration Catheter represents a meaningful advancement in mechanical thrombectomy therapy across EMEA," said Carsten Schroeder, President and CEO of Terumo Neuro. "Its super bore design maximizes aspiration and minimizes flow disruption while delivering exceptional support. It enables physicians to navigate even the most tortuous anatomies in an atraumatic fashion. We're proud that physician preference data so clearly underlines SOFIA Flow 88 catheter's strong performance. It reinforces the SOFIA catheter family's reputation as 'best in class' for trackability, navigation and overall performance."

The SOFIA Flow 88 Neurovascular Aspiration Catheter was commercially launched in the EMEA on June 2, 2025, as the latest addition to Terumo Neuro's global stroke portfolio. Engineered for reliable trackability, proximal stability, and vessel-friendly flexibility, the SOFIA Flow 88 catheter is designed to optimize physician control and integration into a variety of aspiration and combination strategies.

The physician preference data unveiled at ESMINT builds on results from the U.S.-based SOFAST data and the European SESAME Study, which demonstrated the safety and efficacy of the SOFIA™ catheter as a frontline approach in mechanical thrombectomy.

The SOFIA Flow 88 catheter is compatible with the SOFIA™ Plus 6F Aspiration Catheter and is part of Terumo Neuro's fully integrated stroke solution, including:

About Terumo Neuro

We're in business to create and deliver innovations that redefine what's possible in neurovascular treatment, meaningfully advancing both physician practice and patient outcomes. Founded in 1997 as MicroVention and acquired by Terumo Corporation in 2006, Terumo Neuro offers more than thirty products for the treatment of cerebral aneurysms, ischemic stroke, carotid artery disease, and neurovascular malformations. Headquartered in California, Terumo Neuro products are sold in more than seventy countries through a direct sales organization as well as strategic distribution partnerships. Manufacturing facilities are in Aliso Viejo, California, and San José, Costa Rica. For more information, please visit www.terumoneuro.com.

About Terumo Corporation

Terumo (TSE:4543) is a global leader in medical technology and has been committed to "Contributing to Society through Healthcare" for more than 100 years. Based in Tokyo and operating globally, Terumo employs over 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company began as a Japanese thermometer manufacturer and now offers an extensive portfolio—from vascular intervention and cardio-surgical solutions to blood transfusion, cell therapy technology, and essential clinical products.

Reference

Media Contact:
Christine McCullough
Global Corporate Communications
Terumo Neuro
+1 714 206 9800
[email protected]

Info - https://mma.prnewswire.com/media/2762040/Terumo_Neuro_SOFIA_Infographic.jpg

Logo - https://mma.prnewswire.com/media/2613109/Terumo_Neuro___Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/terumo-neuro-unveils-new-sofia-flow-88-neurovascular-aspiration-catheter-data-from-emea-demonstrating-strong-performance-302543901.html